BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20221693)

  • 1. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
    Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
    Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.
    Berman DB; Costalas J; Schultz DC; Grana G; Daly M; Godwin AK
    Cancer Res; 1996 Aug; 56(15):3409-14. PubMed ID: 8758903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
    Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
    Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds.
    Petrukhin L; Dangel J; Vanderveer L; Costalas J; Bellacosa A; Grana G; Daly M; Godwin AK
    Cancer Res; 1997 Dec; 57(24):5480-4. PubMed ID: 9407954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
    Palma MD; Domchek SM; Stopfer J; Erlichman J; Siegfried JD; Tigges-Cardwell J; Mason BA; Rebbeck TR; Nathanson KL
    Cancer Res; 2008 Sep; 68(17):7006-14. PubMed ID: 18703817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
    Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
    Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A family with three germline mutations in BRCA1 and BRCA2.
    Liede A; Metcalfe K; Offit K; Brown K; Miller S; Narod SA; Moslehi R
    Clin Genet; 1998 Sep; 54(3):215-8. PubMed ID: 9788724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
    Robson M; Dabney MK; Rosenthal G; Ludwig S; Seltzer MH; Gilewski T; Haas B; Osborne M; Norton L; Gilbert F; Offit K
    Genet Test; 1997; 1(1):47-51. PubMed ID: 10464625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
    Ganguly A; Leahy K; Marshall AM; Dhulipala R; Godmilow L; Ganguly T
    Genet Test; 1997; 1(2):85-90. PubMed ID: 10464631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
    Gotlieb WH; Friedman E; Bar-Sade RB; Kruglikova A; Hirsh-Yechezkel G; Modan B; Inbar M; Davidson B; Kopolovic J; Novikov I; Ben-Baruch G
    J Natl Cancer Inst; 1998 Jul; 90(13):995-1000. PubMed ID: 9665148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
    Ganguly T; Dhulipala R; Godmilow L; Ganguly A
    Hum Genet; 1998 May; 102(5):549-56. PubMed ID: 9654203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
    Vehmanen P; Friedman LS; Eerola H; McClure M; Ward B; Sarantaus L; Kainu T; Syrjäkoski K; Pyrhönen S; Kallioniemi OP; Muhonen T; Luce M; Frank TS; Nevanlinna H
    Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.
    Lalloo F; Cochrane S; Bulman B; Varley J; Elles R; Howell A; Evans DG
    J Med Genet; 1998 Jan; 35(1):10-2. PubMed ID: 9475087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
    Schubert EL; Lee MK; Mefford HC; Argonza RH; Morrow JE; Hull J; Dann JL; King MC
    Am J Hum Genet; 1997 May; 60(5):1031-40. PubMed ID: 9150150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
    Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
    J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.